163 related articles for article (PubMed ID: 27569424)
21. GPR119 Is a Potent Regulator of Human Sebocyte Biology.
Markovics A; Angyal Á; Tóth KF; Ádám D; Pénzes Z; Magi J; Pór Á; Kovács I; Törőcsik D; Zouboulis CC; Bíró T; Oláh A
J Invest Dermatol; 2020 Oct; 140(10):1909-1918.e8. PubMed ID: 32142797
[TBL] [Abstract][Full Text] [Related]
22. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.
Chepurny OG; Holz GG; Roe MW; Leech CA
Mol Endocrinol; 2016 Jun; 30(6):614-29. PubMed ID: 27082897
[TBL] [Abstract][Full Text] [Related]
23. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
24. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.
Overton HA; Babbs AJ; Doel SM; Fyfe MC; Gardner LS; Griffin G; Jackson HC; Procter MJ; Rasamison CM; Tang-Christensen M; Widdowson PS; Williams GM; Reynet C
Cell Metab; 2006 Mar; 3(3):167-75. PubMed ID: 16517404
[TBL] [Abstract][Full Text] [Related]
25. Rho kinase-dependent desensitization of GPR39; a unique mechanism of GPCR downregulation.
Shimizu Y; Koyama R; Kawamoto T
Biochem Pharmacol; 2017 Sep; 140():105-114. PubMed ID: 28619258
[TBL] [Abstract][Full Text] [Related]
26. Oleoylethanolamide Exhibits GPR119-Dependent Inhibition of Osteoclast Function and GPR119-Independent Promotion of Osteoclast Apoptosis.
Kim HJ; Lee DK; Jin X; Che X; Choi JY
Mol Cells; 2020 Apr; 43(4):340-349. PubMed ID: 32050752
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
Yang Z; Fang Y; Park H
Bioorg Med Chem Lett; 2017 Jun; 27(11):2515-2519. PubMed ID: 28408218
[TBL] [Abstract][Full Text] [Related]
28. Intestinal GPR119 activation by microbiota-derived metabolites impacts feeding behavior and energy metabolism.
Igarashi M; Hayakawa T; Tanabe H; Watanabe K; Nishida A; Kimura I
Mol Metab; 2023 Jan; 67():101649. PubMed ID: 36462626
[TBL] [Abstract][Full Text] [Related]
29. Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy.
Hutch CR; Trakimas DR; Roelofs K; Pressler J; Sorrell J; Cota D; Obici S; Sandoval DA
Ann Surg; 2020 Mar; 271(3):509-518. PubMed ID: 30702457
[TBL] [Abstract][Full Text] [Related]
30. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Holst B; Brandt E; Bach A; Heding A; Schwartz TW
Mol Endocrinol; 2005 Sep; 19(9):2400-11. PubMed ID: 15905359
[TBL] [Abstract][Full Text] [Related]
31. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
[TBL] [Abstract][Full Text] [Related]
32. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists.
Fang Y; Yang Z; Gundeti S; Lee J; Park H
Bioorg Med Chem; 2017 Jan; 25(1):254-260. PubMed ID: 27825553
[TBL] [Abstract][Full Text] [Related]
33. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
Semple G; Ren A; Fioravanti B; Pereira G; Calderon I; Choi K; Xiong Y; Shin YJ; Gharbaoui T; Sage CR; Morgan M; Xing C; Chu ZL; Leonard JN; Grottick AJ; Al-Shamma H; Liang Y; Demarest KT; Jones RM
Bioorg Med Chem Lett; 2011 May; 21(10):3134-41. PubMed ID: 21444206
[TBL] [Abstract][Full Text] [Related]
34. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
[TBL] [Abstract][Full Text] [Related]
35. Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity.
Cornall LM; Hryciw DH; Mathai ML; McAinch AJ
Mol Cell Endocrinol; 2015 Feb; 402():72-85. PubMed ID: 25578601
[TBL] [Abstract][Full Text] [Related]
36. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
37. Mutation-Guided Unbiased Modeling of the Fat Sensor GPR119 for High-Yield Agonist Screening.
Norn C; Hauge M; Engelstoft MS; Kim SH; Lehmann J; Jones RM; Schwartz TW; Frimurer TM
Structure; 2015 Dec; 23(12):2377-2386. PubMed ID: 26526849
[TBL] [Abstract][Full Text] [Related]
38. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
Dhayal S; Morgan NG
Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
[TBL] [Abstract][Full Text] [Related]
39. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists.
Fu S; Xiang W; Chen J; Ma L; Chen L
Chem Biol Drug Des; 2017 May; 89(5):815-819. PubMed ID: 27779815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
